Latest MRSN reports update at 2024-02-28: 2023 ∙ 2022 ∙ 2021

Mersana Therapeutics MRSN

$ 2.47 -27.5%

Mersana Therapeutics Financial Statements 2011-2024 | MRSN

Annual Financial Statements Mersana Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	575 M	567 M	310 M	1.12 B	304 M	105 M	181 M	-	-	-	-	-	-
Shares	116 M	93.7 M	70.6 M	61.5 M	43.5 M	23 M	12 M	-	-	-	-	-	-
Historical Prices	4.95	6.05	4.39	18.2	8.66	5.51	17.3	-	-	-	-	-	-
Net Income	-172 M	-204 M	-170 M	-88 M	-28.2 M	-64.3 M	-38.7 M	-13.7 M	-16.4 M	-	-	-	-
Revenue	36.9 M	26.6 M	43 K	828 K	42.1 M	10.6 M	17.5 M	25.2 M	10.4 M	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	4.07 M	3.33 M	1.27 M	359 K	234 K	-	-	-	-89 K	-	-	-	-
EBITDA	1.52 M	927 K	855 K	1.01 M	-29 M	-64.4 M	-38.7 M	-13.2 M	-16 M	-	-	-	-
Operating Expenses	217 M	230 M	169 M	88.9 M	72.3 M	76.2 M	57.2 M	-	-	-	-	-	-
General and Administrative Expenses	59.5 M	57 M	36.9 M	21.9 M	17.3 M	16.3 M	10.5 M	6.98 M	5.35 M	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Mersana Therapeutics

	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	121 M	116 M	108 M	105 M	97.6 M	95.8 M	79.9 M	73.7 M	71.8 M	69.6 M	69 M	68.6 M	68.4 M	60.7 M	48 M	47.9 M	47.8 M	47.7 M	30.3 M	23.2 M	23.2 M	23 M	22.8 M	22.8 M	22.2 M	1.41 M	1.34 M	1.29 M	1.28 M	1.25 M	1.24 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-41.7 M	-54.3 M	-56.2 M	-	-59.8 M	-52.2 M	-47.3 M	-	-45.5 M	-40.9 M	-34.7 M	-28.8 M	-22.5 M	-28.8 M	-28.8 M	-16.2 M	-16.2 M	-16.2 M	-16.2 M	-22.4 M	-22.4 M	-22.4 M	-22.4 M	-14 M	-38.7 M	-38.7 M	-38.7 M	1.26 M	-13.7 M	-13.7 M	-5.36 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	7.7 M	10.7 M	7.8 M	-	5.57 M	4.28 M	2.04 M	-	11 K	11 K	11 K	10 K	11 K	796 K	11 K	42 K	844 K	202 K	41 M	1.19 M	2.15 M	4.19 M	3.06 M	3.26 M	6.27 M	3.73 M	4.29 M	12 M	3.26 M	6.22 M	3.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	1.02 M	1.02 M	983 K	-	880 K	760 K	724 K	-	98 K	95 K	93 K	92 K	92 K	87 K	88 K	87 K	107 K	40 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	319 K	-	645 K	432 K	205 K	-	644 K	432 K	226 K	-	750 K	494 K	248 K	-	963 K	653 K	337 K	-	907 K	565 K	258 K	-	673 K	438 K	209 K	-	449 K	265 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	51.6 M	67.2 M	65.6 M	-	65.2 M	56 M	48.6 M	-	45.4 M	40.8 M	34.6 M	28.8 M	22.4 M	20.6 M	17.2 M	16.6 M	18.1 M	18 M	19.6 M	24 M	19.6 M	16.9 M	15.8 M	17.6 M	14.3 M	12.8 M	12.4 M	10.8 M	9.15 M	10 M	9.06 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	12.9 M	18.2 M	18.3 M	-	14.6 M	14.8 M	12.8 M	-	10.1 M	8.88 M	7.21 M	5.91 M	5.88 M	5.17 M	4.94 M	4.21 M	4.44 M	4.19 M	4.44 M	4.15 M	4.38 M	4.23 M	3.57 M	3.06 M	2.9 M	2.2 M	2.3 M	1.94 M	1.6 M	1.83 M	1.62 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency